ClinicalTrials.gg
CompletedNCT02680574Updated Jun 27, 2022Results posted

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

A Phase 3 interventional study of Vadadustat and Darbepoetin alfa in Anemia and Non-Dialysis-Dependent Chronic Kidney Disease, sponsored by Akebia Therapeutics. Completed at 503 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-27.

Sponsored by Akebia Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,725
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
4th of 27
1,725 · median 60
Started
2016
with 4 others
Phase 3
14 of 27
none open now
Registered
9th of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 4th largest by enrollment, is one of 5 that started in 2016, is one of 14 in phase 3, and was the 9th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Read the detailed description

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of Vadadustat versus Darbepoetin alfa for the maintenance treatment of anemia in participants with NDD-CKD

03

Conditions studied

  • Anemia
  • Non-Dialysis-Dependent Chronic Kidney Disease

Keywords

  • Vadadustat
  • AKB-6548
  • Chronic kidney disease
  • anemia
  • CKD
  • chronic renal insufficiency
  • renal impairment
  • erythropoietin
  • kidney
  • renal
  • oral anemia treatment
  • hemoglobin
  • hypoxia-inducible factor
  • HIF
  • hypoxia-inducible factor prolyl-hydroxylase inhibitor
  • HIF-PHI
  • efficacy
  • safety
  • Phase 3
  • cardiovascular
  • NDD-CKD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • Diagnosis of chronic kidney disease (CKD) with an estimated ≤60 milliliters per minute per 1.73 square meter (mL/min/1.73 m\^2) at Screening and not expected to start dialysis within 6 months of Screening
  • Currently maintained on erythropoiesis-stimulating agents therapy, with a dose received within 6 weeks prior to or during Screening
  • Mean Screening between 8.0 and 11.0 grams per deciliter (g/dL) (inclusive) in the United States (US) and between 9.0 and 12.0 g/dL (inclusive) outside of the US
  • Serum ferritin ≥100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) ≥20% during Screening

Exclusion criteria

Exclusion Criteria:

  • Anemia due to a cause other than CKD or participant with active bleeding or recent blood loss
  • Red blood cell transfusion within 8 weeks prior to randomization
  • Uncontrolled hypertension
  • Severe heart failure at Screening ( Class IV)
  • Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular, or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for heart failure, or stroke within 12 weeks prior to or during Screening
  • to Darbepoetin or Vadadustat or to any of their
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,725 participants (actual)

Study arms

  • Experimental
    Vadadustat

    Drug: Vadadustat

  • Active comparator
    Darbepoetin alfa

    Drug: Darbepoetin alfa

Interventions

  • Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

    Also known as: AKB-6548

  • Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.

    Also known as: Aranesp

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)

    The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Primary Efficacy Period was calculated as the average Hb value over Weeks 24 to 36. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with Baseline hemoglobin concentration (\<10.0 versus ≥10.0 g/dL), geographic region (United States \[US\] versus European Union \[EU\] versus Rest of World \[ROW\]), and New York Heart Association congestive heart failure (NYHA CHF) class (Class 0 \[no CHF\] or I versus II or III) as covariates.

    Time frame: Baseline; Weeks 24 to 36

  2. Median Time to First Major Adverse Cardiovascular Event (MACE)

    MACE was defined as all-cause mortality, non-fatal myocardial infarction (MI), or non-fatal stroke. The primary safety outcome was positively adjudicated first MACE, which was defined as any death, Endpoint Adjudication Committee (EAC)-confirmed non-fatal MI, or EAC-confirmed non-fatal stroke occurring between the first dose date and each participant's last participation date. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0015 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to Week 208

Secondary outcomes

  1. Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)

    The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Secondary Efficacy Period was calculated as the average Hb value over Weeks 40 to 52. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with Baseline hemoglobin concentration (\<10.0 versus ≥10.0 g/dL), geographic region (US versus EU versus ROW), and NYHA CHF class (Class 0 \[no CHF\] or I versus II or III) as covariates.

    Time frame: Baseline; Weeks 40 to 52

  2. Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis

    MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Hospitalization for EAC adjudicated heart failure included presentation of participants to an acute care facility requiring an overnight hospitalization (change in calendar day) with an exacerbation of heart failure requiring treatment. EAC confirmed thromboembolic events for this secondary outcome measure included arterial thrombosis, deep vein thrombosis, and pulmonary embolism. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0015 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to Week 208

  3. Median Time to First Cardiovascular MACE

    MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Cardiovascular MACE analysis differed from the primary MACE endpoint as it included only deaths adjudicated by the EAC as cardiovascular deaths (i.e, only EAC-confirmed cardiovascular deaths) in addition to first events of non-fatal MI or non-fatal stroke. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0015 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to Week 208

  4. Median Time to First Cardiovascular Death

    Cardiovascular death included EAC adjudicated fatal MI, pump failure, sudden death, presumed sudden death, fatal stroke, fatal pulmonary embolism, cardiovascular procedure-related death, other cardiovascular death, and presumed cardiovascular death. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0015 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to Week 208

  5. Median Time to First All-cause Mortality

    Only events that were positively adjudicated and confirmed by the EAC were included in the MACE analyses. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0015 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to Week 208

Other outcomes

  1. Exploratory - Proportion of Participants With Hb Values Within the Target Range During the Primary Evaluation Period (Weeks 24 to 36)

    Time frame: Weeks 24 to 36

  2. Exploratory - Proportion of Time With Hb Values Within the Target Range During the Primary Evaluation Period (Weeks 24 to 36)

    Time frame: Weeks 24 to 36

  3. Exploratory - Proportion of Time With Hb Values Within the Target Range During the Secondary Evaluation Period (Weeks 40 to 52)

    Time frame: Weeks 40 to 52

  4. Exploratory - Proportion of Participants With Hb Values Within the Target Range During the Secondary Evaluation Period (Weeks 40 to 52)

    Time frame: Weeks 40 to 52

  5. Exploratory - Proportion of Participants With an Hb Increase of >1.0 g/dL From Baseline Visit

    Time frame: Baseline; up to Week 52

  6. Exploratory - Time to Achieve Hb Increase of >1.0 g/dL From Baseline Visit

    Time frame: Baseline; up to Week 52

  7. Exploratory - Mean Change in Hb Between Baseline (Mean Pretreatment Hb) and the Primary Evaluation Period (Mean Hb From Weeks 24 to 36) Stratified by Pre-baseline Erythropoiesis-stimulating Agent (ESA) Exposure

    Time frame: Baseline; Weeks 24 to 36

  8. Exploratory - Mean Monthly Dose of Intravenous (IV) Elemental Iron Administered in Participants Who Have Received IV Iron

    Time frame: Up to Week 52

  9. Exploratory - Proportion of Participants Receiving IV Iron Therapy

    Time frame: Up to Week 52

  10. Exploratory - Proportion of Participants Receiving Red Blood Cells (RBCs) Transfusion(s)

    Time frame: Up to Week 52

07

Results

Posted Jun 27, 2022

Participant flow

Participant flow — Overall Study
MilestoneVadadustatDarbepoetin Alfa
Started862863
Completed704711
Not completed158152
Withdrew: Death137137
Withdrew: Withdrawal by subject179
Withdrew: Lost to follow-up46

Outcome measures

PrimaryChange From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)

The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Primary Efficacy Period was calculated as the average Hb value over Weeks 24 to 36. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with Baseline hemoglobin concentration (\<10.0 versus ≥10.0 g/dL), geographic region (United States \[US\] versus European Union \[EU\] versus Rest of World \[ROW\]), and New York Heart Association congestive heart failure (NYHA CHF) class (Class 0 \[no CHF\] or I versus II or III) as covariates.

Time frame:
Baseline; Weeks 24 to 36
Reported as:
Least squares mean · Grams per deciliter (g/dL)
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)
Grams per deciliter (g/dL)VadadustatDarbepoetin Alfa
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)0.41 ± 0.0360.42 ± 0.037
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Least squares mean difference: -0.01 · 95% CI -0.09 to 0.07
PrimaryMedian Time to First Major Adverse Cardiovascular Event (MACE)

MACE was defined as all-cause mortality, non-fatal myocardial infarction (MI), or non-fatal stroke. The primary safety outcome was positively adjudicated first MACE, which was defined as any death, Endpoint Adjudication Committee (EAC)-confirmed non-fatal MI, or EAC-confirmed non-fatal stroke occurring between the first dose date and each participant's last participation date. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0015 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to Week 208
Reported as:
Median · Weeks
Median Time to First Major Adverse Cardiovascular Event (MACE)
WeeksVadadustatDarbepoetin Alfa
Median Time to First Major Adverse Cardiovascular Event (MACE)53.21 (30.64 to 81.43)58.00 (31.07 to 99.21)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.2015 · Hazard ratio (hr): 1.16 · 95% CI 0.930 to 1.446Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.0725 · Hazard ratio (hr): 1.17 · 95% CI 1.012 to 1.355Based on non-parametric analysis.
SecondaryChange From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)

The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Secondary Efficacy Period was calculated as the average Hb value over Weeks 40 to 52. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with Baseline hemoglobin concentration (\<10.0 versus ≥10.0 g/dL), geographic region (US versus EU versus ROW), and NYHA CHF class (Class 0 \[no CHF\] or I versus II or III) as covariates.

Time frame:
Baseline; Weeks 40 to 52
Reported as:
Least squares mean · g/dL
Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)
g/dLVadadustatDarbepoetin Alfa
Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)0.43 ± 0.0440.44 ± 0.044
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Least squares mean difference: -0.00 · 95% CI -0.10 to 0.09
SecondaryMedian Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis

MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Hospitalization for EAC adjudicated heart failure included presentation of participants to an acute care facility requiring an overnight hospitalization (change in calendar day) with an exacerbation of heart failure requiring treatment. EAC confirmed thromboembolic events for this secondary outcome measure included arterial thrombosis, deep vein thrombosis, and pulmonary embolism. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0015 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to Week 208
Reported as:
Median · Weeks
Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis
WeeksVadadustatDarbepoetin Alfa
Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis48.29 (22.71 to 72.71)49.29 (20.14 to 86.43)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.7770 · Hazard ratio (hr): 1.04 · 95% CI 0.851 to 1.268Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.2305 · Hazard ratio (hr): 1.11 · 95% CI 0.972 to 1.267Based on non-parametric analysis.
SecondaryMedian Time to First Cardiovascular MACE

MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Cardiovascular MACE analysis differed from the primary MACE endpoint as it included only deaths adjudicated by the EAC as cardiovascular deaths (i.e, only EAC-confirmed cardiovascular deaths) in addition to first events of non-fatal MI or non-fatal stroke. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0015 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to Week 208
Reported as:
Median · Weeks
Median Time to First Cardiovascular MACE
WeeksVadadustatDarbepoetin Alfa
Median Time to First Cardiovascular MACE45.57 (20.14 to 67.57)50.29 (18.29 to 83.29)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Gray's Test · p = =0.5509 · Hazard ratio (hr): 1.11 · 95% CI 0.817 to 1.501Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Gray's Test · p = =0.2531 · Hazard ratio (hr): 1.16 · 95% CI 0.947 to 1.420Based on non-parametric analysis.
SecondaryMedian Time to First Cardiovascular Death

Cardiovascular death included EAC adjudicated fatal MI, pump failure, sudden death, presumed sudden death, fatal stroke, fatal pulmonary embolism, cardiovascular procedure-related death, other cardiovascular death, and presumed cardiovascular death. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0015 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to Week 208
Reported as:
Median · Weeks
Median Time to First Cardiovascular Death
WeeksVadadustatDarbepoetin Alfa
Median Time to First Cardiovascular Death48.29 (29.50 to 69.14)54.21 (30.71 to 94.14)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Gray's test · p = =0.4184 · Hazard ratio (hr): 0.88 · 95% CI 0.610 to 1.258Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Gray's test · p = =0.8613 · Hazard ratio (hr): 1.01 · 95% CI 0.792 to 1.293Based on non-parametric analysis.
SecondaryMedian Time to First All-cause Mortality

Only events that were positively adjudicated and confirmed by the EAC were included in the MACE analyses. PROTECT MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0014 (NCT02648347) and AKB-6548-CI-0015 (NCT02680574). Results and statistical analysis from study AKB-6548-CI-0015 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0014 and AKB-6548-CI-0015 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to Week 208
Reported as:
Median · Weeks
Median Time to First All-cause Mortality
WeeksVadadustatDarbepoetin Alfa
Median Time to First All-cause Mortality57.71 (35.29 to 87.00)62.14 (34.14 to 111.57)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.8041 · Hazard ratio (hr): 1.04 · 95% CI 0.820 to 1.315Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.4577 · Hazard ratio (hr): 1.09 · 95% CI 0.930 to 1.274
Other pre-specifiedExploratory - Proportion of Participants With Hb Values Within the Target Range During the Primary Evaluation Period (Weeks 24 to 36)
Time frame:
Weeks 24 to 36

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Time With Hb Values Within the Target Range During the Primary Evaluation Period (Weeks 24 to 36)
Time frame:
Weeks 24 to 36

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Time With Hb Values Within the Target Range During the Secondary Evaluation Period (Weeks 40 to 52)
Time frame:
Weeks 40 to 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Participants With Hb Values Within the Target Range During the Secondary Evaluation Period (Weeks 40 to 52)
Time frame:
Weeks 40 to 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Participants With an Hb Increase of >1.0 g/dL From Baseline Visit
Time frame:
Baseline; up to Week 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Time to Achieve Hb Increase of >1.0 g/dL From Baseline Visit
Time frame:
Baseline; up to Week 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Mean Change in Hb Between Baseline (Mean Pretreatment Hb) and the Primary Evaluation Period (Mean Hb From Weeks 24 to 36) Stratified by Pre-baseline Erythropoiesis-stimulating Agent (ESA) Exposure
Time frame:
Baseline; Weeks 24 to 36

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Mean Monthly Dose of Intravenous (IV) Elemental Iron Administered in Participants Who Have Received IV Iron
Time frame:
Up to Week 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Participants Receiving IV Iron Therapy
Time frame:
Up to Week 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Participants Receiving Red Blood Cells (RBCs) Transfusion(s)
Time frame:
Up to Week 52

Results for this outcome have not been posted.

Adverse events

Collected over Up to 208 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vadadustat139/861 (16.1%)504/861 (58.5%)482/861 (56%)
Darbepoetin Alfa139/862 (16.1%)488/862 (56.6%)436/862 (50.6%)
Most frequent serious events
Showing 10 of 615
Most frequent serious events
EventVadadustatDarbepoetin Alfa
End stage renal diseaseRenal and urinary disorders232/861238/862
PneumoniaInfections and infestations56/86149/862
Acute kidney injuryRenal and urinary disorders34/86132/862
Acute myocardial infarctionCardiac disorders34/86124/862
Cardiac failure congestiveCardiac disorders29/86131/862
Urinary tract infectionInfections and infestations20/86120/862
DeathGeneral disorders20/86113/862
Cardiac failureCardiac disorders10/86119/862
AnaemiaBlood and lymphatic system disorders16/86118/862
SepsisInfections and infestations17/86116/862
Most frequent other events
Showing 10 of 13
Most frequent other events
EventVadadustatDarbepoetin Alfa
HypertensionVascular disorders120/861123/862
DiarrhoeaGastrointestinal disorders117/86176/862
Urinary tract infectionInfections and infestations93/861113/862
Oedema peripheralGeneral disorders84/86185/862
HyperkalaemiaMetabolism and nutrition disorders71/86178/862
NauseaGastrointestinal disorders73/86157/862
FallInjury, poisoning and procedural complications64/86153/862
NasopharyngitisInfections and infestations53/86161/862
Upper respiratory tract infectionInfections and infestations55/86144/862
ArthralgiaMusculoskeletal and connective tissue disorders42/86148/862

Baseline characteristics

Age, Continuous
Age, Continuous(Years)VadadustatDarbepoetin AlfaTotal
Mean67.3 ± 13.1466.5 ± 13.5266.9 ± 13.33
Sex: Female, Male
Sex: Female, Male(Participants)VadadustatDarbepoetin AlfaTotal
Female468488956
Male394375769
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VadadustatDarbepoetin AlfaTotal
American Indian or Alaska Native322658
Asian6255117
Black or African American93131224
Native Hawaiian or Other Pacific Islander303
White6316031234
Not Reported151328
Reported as Other253257
Multiple134
Average hemoglobin
Average hemoglobin(Grams per deciliter (g/dL))VadadustatDarbepoetin AlfaTotal
Mean10.423 ± 0.887110.390 ± 0.943010.406 ± 0.9154
Mean estimated glomerular filtration rate
Mean estimated glomerular filtration rate(mL/min/1.73m^2)VadadustatDarbepoetin AlfaTotal
Mean22.6 ± 11.6422.8 ± 12.0422.7 ± 11.84
Number of Participants with History of Diabetes
Number of Participants with History of Diabetes(Participants)VadadustatDarbepoetin AlfaTotal
Count of participants444432876
Number of Participants with NYHA Functional Classification of Heart Failure
Number of Participants with NYHA Functional Classification of Heart Failure(Participants)VadadustatDarbepoetin AlfaTotal
NYHA Class 06105951205
NYHA Class I108108216
NYHA Class II113122235
NYHA Class III293665
NYHA Class IV000
NYHA Class Missing224
Number of Participants with Any History of Heart Failure
Number of Participants with Any History of Heart Failure(Participants)VadadustatDarbepoetin AlfaTotal
Yes445296
No6135951208
Missing205216421
08

Study locations

503 sites
  • Research Site
    Birmingham, Alabama 35211, United States
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    Tuscumbia, Alabama 35674, United States
  • Research Site
    Glendale, Arizona 85306, United States
  • Research Site
    Mesa, Arizona 85210, United States
  • Research Site
    Phoenix, Arizona 85027, United States
  • Research Site
    Tucson, Arizona 85718, United States
  • Research Site
    Tucson, Arizona 85724, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Bakersfield, California 93309, United States
  • Research Site #1
    Chula Vista, California 91910, United States
  • Research Site #2
    Chula Vista, California 91910, United States
  • Research Site
    El Centro, California 92243, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Granada Hills, California 91344, United States
  • Research Site
    La Mesa, California 91942, United States
  • Research Site
    Laguna Hills, California 92653, United States
  • Research Site
    Long Beach, California 90807, United States
  • Research Site
    Long Beach, California 92886, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Lynwood, California 90260, United States
  • Research Site #1
    Northridge, California 91324, United States
  • Research Site #2
    Northridge, California 91324, United States
  • Research Site
    Riverside, California 92505, United States
  • Research Site
    Roseville, California 95661, United States
  • Research Site
    Salinas, California 93901, United States
  • Research Site
    San Diego, California 92103-6204, United States
  • Research Site #1
    San Dimas, California 91773, United States
  • Research Site #2
    San Dimas, California 91773, United States
  • Research Site
    Santa Ana, California 92704, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Sherman Oaks, California 91403, United States
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Whittier, California 90603, United States
  • Research Site
    Whittier, California 99999, United States
  • Research Site
    Arvada, Colorado 80002, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Westminster, Colorado 80031, United States
  • Research Site
    Stamford, Connecticut 06902, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Bradenton, Florida 34209, United States
  • Research Site
    Brandon, Florida 33511, United States
  • Research Site
    Cooper City, Florida 33024, United States
  • Research Site #1
    Coral Gables, Florida 33134, United States
  • Research Site #2
    Coral Gables, Florida 33134, United States
  • Research Site
    Coral Springs, Florida 33065, United States
  • Research Site
    Coral Springs, Florida 33071, United States
  • Research Site
    Doral, Florida 33166, United States
  • Research Site
    Edgewater, Florida 32132, United States
  • Research Site
    Hialeah, Florida 33010, United States
  • Research Site #1
    Hialeah, Florida 33012, United States
  • Research Site #2
    Hialeah, Florida 33012, United States
  • Research Site #3
    Hialeah, Florida 33012, United States
  • Research Site
    Hialeah, Florida 33018, United States
  • Research Site #1
    Hollywood, Florida 33024, United States
  • Research Site #2
    Hollywood, Florida 33024, United States
  • Research Site
    Jacksonville, Florida 32204, United States
  • Research Site #1
    Jacksonville, Florida 32216, United States
  • Research Site #2
    Jacksonville, Florida 32216, United States
  • Research Site
    Lake Worth, Florida 33467, United States
  • Research Site
    Lauderdale Lakes, Florida 33313, United States
  • Research Site
    Miami Beach, Florida 33140, United States
  • Research Site
    Miami Lakes, Florida 33014, United States
  • Research Site #1
    Miami Lakes, Florida 33016, United States
  • Research Site #2
    Miami Lakes, Florida 33016, United States
  • Research Site
    Miami, Florida 33122, United States
  • Research Site
    Miami, Florida 33125-4141, United States
  • Research Site #1
    Miami, Florida 33126, United States
  • Research Site #2
    Miami, Florida 33126, United States
  • Research Site
    Miami, Florida 33133, United States
  • Research Site
    Miami, Florida 33134, United States
  • Research Site
    Miami, Florida 33135, United States
  • Research Site
    Miami, Florida 33143, United States
  • Research Site #1
    Miami, Florida 33144, United States
  • Research Site #2
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33145, United States
  • Research Site
    Miami, Florida 33150, United States
  • Research Site
    Miami, Florida 33157, United States
  • Research Site
    Miami, Florida 33165, United States
  • Research Site
    Miami, Florida 33169, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site #1
    Miami, Florida 33175, United States
  • Research Site #2
    Miami, Florida 33175, United States
  • Research Site
    Pembroke Pines, Florida 33026, United States
  • Research Site
    Pompano Beach, Florida 33060, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Tampa, Florida 33604, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Tampa, Florida 33614, United States
  • Research Site
    Atlanta, Georgia 30338, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Atlanta, Georgia 30350, United States
  • Research Site
    Augusta, Georgia 30909, United States
  • Research Site
    Columbus, Georgia 31901, United States
  • Research Site #1
    Columbus, Georgia 31904, United States
  • Research Site #2
    Columbus, Georgia 31904, United States
  • Research Site #1
    Lawrenceville, Georgia 30046, United States
  • Research Site #2
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Macon, Georgia 31217, United States

Showing the first 100 of 503 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Chertow GM, Pergola PE, Farag YMK, Agarwal R, Arnold S, Bako G, Block GA, Burke S, Castillo FP, Jardine AG, Khawaja Z, Koury MJ, Lewis EF, Lin T, Luo W, Maroni BJ, Matsushita K, McCullough PA, Parfrey PS, Roy-Chaudhury P, Sarnak MJ, Sharma A, Spinowitz B, Tseng C, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Eckardt KU; PRO2TECT Study Group. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021 Apr 29;384(17):1589-1600. doi: 10.1056/NEJMoa2035938. PubMed 33913637 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Jun 2020, 52 months.

Results were first posted in Jun 2022, 2 years after primary completion. A results delay was requested in Jun 2021.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 52 months is above that.

Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2016
First posted
Feb 11, 2016
StartActual
Feb 2016
Primary completionActual
Jun 18, 2020
CompletionActual
Jul 31, 2020
Results delay requested
Jun 17, 2021
Results first posted
Jun 27, 2022
Last update
Jun 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02680574
Responsible party
Sponsor
First posted
Feb 11, 2016
Start date
Feb 2016
Primary completion
Jun 18, 2020
Completion
Jul 31, 2020
Results posted
Jun 27, 2022
Last update
Jun 27, 2022

Study contacts

Chief Medical Officer
study director · Akebia Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion